Keywords: Biotech predictions, Burrill & Co, Fundraisingm IPOs, Financingm M&A, Regulatory, Biosimilars

Biotech predictions for 2012 from sector specialist Steven Burrill

Article | 03 January 2012

As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm Burrill & Co, issued ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in